Disseminated <i>Mycobacterium avium</i> Complex Infection Following CD3/CD20 Bispecific Antibody Therapy in a Patient With Follicular Lymphoma-Reference-Cited by-同舟云学术

Disseminated Mycobacterium avium Complex Infection Following CD3/CD20 Bispecific Antibody Therapy in a Patient With Follicular Lymphoma

Published:2024-08-08 Issue:9 Volume:11 Page:
ISSN:2328-8957
Container-title:Open Forum Infectious Diseases
language:en
Short-container-title:

Author:

Little Jessica S¹²³^ORCID,Hurtado Rocio M²⁴,Boire Nicholas²⁵,Baden Lindsey R¹²³,Laga Alvaro C²⁵,Silk Ann W²⁶,Jacobson Caron A²³

Affiliation:

1. Division of Infectious Diseases, Brigham and Women's Hospital , Boston, Massachusetts , USA

2. Harvard Medical School , Boston, Massachusetts , USA

3. Stem Cell Transplant and Cellular Therapy, Dana-Farber Cancer Institute , Boston, Massachusetts , USA

4. Division of Infectious Diseases, Massachusetts General Hospital , Boston, Massachusetts , USA

5. Division of Pathology, Brigham and Women's Hospital , Boston, Massachusetts, USA

6. Department of Medical Oncology, Dana-Farber Cancer Institute , Boston, Massachusetts, USA

Abstract

Abstract Infections remain a major concern following bispecific antibody therapy but are not well described in pivotal trials. We present the first well-documented case of a classic but rare opportunistic infection, disseminated Mycobacterium avium complex, in a patient receiving bispecific antibody therapy.

Publisher

Oxford University Press (OUP)

Link

https://academic.oup.com/ofid/advance-article-pdf/doi/10.1093/ofid/ofae460/58775514/ofae460.pdf

Reference13 articles.

1. Consensus position statement on advancing the standardised reporting of infection events in immunocompromised patients;Teh;Lancet Infect Dis,2024

2. Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel;Raje;Blood Cancer J,2023

3. The present and future of bispecific antibodies for cancer therapy;Klein;Nat Rev Drug Discov,2024

4. Bispecific antibody therapy, its use and risks for infection: bridging the knowledge gap;Longhitano;Blood Rev,2021

5. Acknowledging infection risk in bispecific antibody trials in the treatment of multiple myeloma;Cliff;J Clin Oncol,2023